PRP4K is a HER2-regulated modifier of taxane sensitivity

Related Experiment Video

Updated: Apr 18, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

Dale P Corkery1, Cécile Le Page, Liliane Meunier

  • 1a Department of Biochemistry & Molecular Biology ; Dalhousie University ; Halifax , NS Canada.

Cell Cycle (Georgetown, Tex.)
|January 21, 2015
PubMed

Insights

The pre-mRNA splicing factor 4 kinase (PRP4K) is regulated by HER2 signaling and impacts taxane sensitivity in breast and ovarian cancers. High PRP4K expression may predict better survival in ovarian cancer patients treated with taxanes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Taxanes are crucial chemotherapeutics for breast and ovarian cancers, targeting microtubules.
  • HER2 (Human Epidermal Growth Factor Receptor 2) status influences taxane efficacy and patient survival.
  • PRP4K (pre-mRNA splicing factor 4 kinase) is involved in the spindle assembly checkpoint (SAC) and responds to microtubule-targeting drugs.

Purpose of the Study:

  • To investigate the relationship between PRP4K expression, HER2 status, and taxane sensitivity in breast and ovarian cancers.
  • To determine if PRP4K acts as a modifier of taxane sensitivity regulated by HER2 signaling.
  • To evaluate the prognostic value of PRP4K in ovarian cancer patients treated with taxane-based therapy.

Main Methods:

  • Correlation analysis of PRP4K expression and HER2 status in patient tumor samples.
  • Experimental manipulation (knock-down) of PRP4K in cancer cell lines to assess taxane sensitivity.
  • Survival analysis of ovarian cancer patients based on HER2 and PRP4K expression levels and treatment response.

Main Results:

  • A positive correlation was observed between PRP4K expression and HER2 status in breast and ovarian tumors, indicating HER2-mediated regulation of PRP4K.
  • Knock-down of PRP4K decreased sensitivity to taxanes in cancer cell lines.
  • Low PRP4K levels were associated with acquired taxane resistance.
  • In high-grade serous ovarian cancer, high HER2 levels correlated with poor survival, but high PRP4K expression predicted better survival in the low HER2 subgroup treated with platinum/taxane therapy.

Conclusions:

  • PRP4K is a HER2-regulated protein that modulates taxane sensitivity in breast and ovarian cancers.
  • PRP4K expression levels may serve as a prognostic biomarker for improved survival in ovarian cancer patients undergoing taxane-based treatment.
Keywords:
HER2HER2, human epidermal growth factor receptor 2PRP4KPRP4K, pre-mRNA splicing factor-4 kinaseSAC, spindle assembly checkpointTMA, tissue microarraybreast cancerovarian cancertaxane sensitivity

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72